Two important catalysts highlighted at JPM
$NKTR-214 long-awaited lung cancer data not until ESMO
$CLVS bladder cancer initial data likely at ESMO too, potentially registrational and first PARPi to mkt in bladder
#ESMO19 is shaping up to be a big mtg for biotech again this yr!